How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

Cite this paper

@article{Szturz2017HowSI, title={How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?}, author={Petr Szturz and Tanguy Y. Seiwert and Jan Baptist Vermorken}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2017}, volume={35 20}, pages={2229-2231} }